These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26579546)

  • 1. HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions.
    Rubens M; Ramamoorthy V; Saxena A; Shehadeh N; Appunni S
    J Immunol Res; 2015; 2015():560347. PubMed ID: 26579546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiny steps towards an HIV vaccine.
    Willyard C
    Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Stephenson KE; Wagh K; Korber B; Barouch DH
    Annu Rev Immunol; 2020 Apr; 38():673-703. PubMed ID: 32340576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination.
    Martinez DR; Permar SR; Fouda GG
    Clin Vaccine Immunol; 2016 Feb; 23(2):84-94. PubMed ID: 26656117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches to HIV vaccine development.
    Haynes BF
    Curr Opin Immunol; 2015 Aug; 35():39-47. PubMed ID: 26056742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infectious disease. An enterprising time for HIV vaccine research.
    Cohen J
    Science; 2012 Sep; 337(6101):1446. PubMed ID: 22997300
    [No Abstract]   [Full Text] [Related]  

  • 10. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
    Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
    Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased frequencies of CD8
    Palmer CD; Romero-Tejeda M; Scully EP; Lockhart A; Seaman MS; Goldenthal A; Piechocka-Trocha A; Walker BD; Chibnik LB; Jost S; Porichis F
    J Int AIDS Soc; 2016; 19(1):21136. PubMed ID: 27938646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus vaccines.
    Goepfert P; Bansal A
    Infect Dis Clin North Am; 2014 Dec; 28(4):615-31. PubMed ID: 25287587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV vaccine development--improving on natural immunity.
    Johnston MI; Fauci AS
    N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
    [No Abstract]   [Full Text] [Related]  

  • 15. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines.
    Koff WC; Russell ND; Walport M; Feinberg MB; Shiver JW; Karim SA; Walker BD; McGlynn MG; Nweneka CV; Nabel GJ
    Vaccine; 2013 Apr; 31 Suppl 2():B204-8. PubMed ID: 23598483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
    Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
    Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A brief history of the global effort to develop a preventive HIV vaccine.
    Esparza J
    Vaccine; 2013 Aug; 31(35):3502-18. PubMed ID: 23707164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New hope for an AIDS vaccine.
    Robinson HL
    Nat Rev Immunol; 2002 Apr; 2(4):239-50. PubMed ID: 12001995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA and other technologies for HIV vaccines.
    Bowers M
    BETA; 1998 Apr; ():9-12, 28. PubMed ID: 11365275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.